Company: SXTPW
Filing Date: 2025-08-15
Form Type: PRE 14A
Source: 0001213900-25-077435
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-15
Form: PRE 14A
Chunk 32
---
             | 148,672 |     |            |       - |     |             |      - |     |              |      - |     |       | 148,672 |
| Kristen Landon                               |     | 2024 |     | $           | 300,000 |     | $          | 113,570 |     | $           | 38,125 |     | $            | 19,167 |     | $     | 470,862 |
| Chief Commercial Officer                     |     | 2023 |     |             |       - |     |            |       - |     |             |      - |     |              |      - |     |       |       - |
|                                              |     | 2022 |     |             |       - |     |            |       - |     |             |      - |     |              |      - |     |       |       - |

| (1) | We periodically review, and                                                                                                    
 may increase, base salaries in accordance with our normal annual compensation review for each of our named executive officers. |

Equity Awards

On July 12, 2023, Dr.
Dow was granted a five-year option to purchase a total of 250 shares of our common stock on the last day of each quarter in each calendar
year (for a cumulative total or no more than 5,000 shares over five years) and (ii) Mr. Miller was granted a five-year option to purchase
a total of 200 shares of our common stock on the last day of each quarter in each calendar year (for a cumulative total or no more than
4,000 shares over five years). The per share exercise price of the options were initially equal to the per share closing price of our
common stock on the date of grant and had a cashless exercise provision. In November 2023, the Board reset the exercise price of the options
to be equal to $60.00 and modified the vesting provisions of the option to vest annually over five years, rather than quarterly, with
the first vesting date being December 31, 2024. The initial grant and subsequent amendment of these options was contingent upon
the stockholders of the Company approving the amendment to the exercise price of the options and approving the amendment to the 2022 Plan
to increase the number of shares available under the 2022 Plan in order to comply with Listing Rule 5635(c) of The Nasdaq Stock Market
LL